L26/P-475 Endometrial metabolomic profiling reveals disruption of fatty-acid metabolism in unexplained recurrent pregnancy loss
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Boguenet und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Is there a specific plasma or endometrial metabolomic profile associated with repeated implantation failures (RIF) and/or unexplained recurrent pregnancy loss (U-RPL)? Summary answer A disruption in fatty acid metabolism was specifically found in the endometrium during the implantation phase in patients with a history of U-RPL. What is known already Embryonic implantation is a highly complex process involving endometrial receptivity, embryonic viability and a complex paracrine dialogue between these two partners. RIF and U-RPL are the primary implantation disorders in the context of in vitro fertilization (IVF). Metabolomics, a powerful hypothesis-free approach, enables the characterization of underlying pathological phenotypes. However, no metabolomics study has simultaneously investigated both blood and endometrial tissue in patients with these implantation disorders. Study design, size, duration We performed a prospective observational study of the plasma and endometrium from 80 women undergoing assisted reproductive technology (ART) at Angers University Hospital, France, between October 2017 and October 2020. The women were classified in three groups: 19 women with U-RPL, 41 women with RIF and 20 women undergoing ART for male-factor infertility, serving as controls. Participants/materials, setting, methods A blood sample and an endometrial biopsy were collected during the window of implantation, 5 to 9 days after ovulation. Targeted and quantitative metabolomics analyses were performed using high-performance liquid chromatography coupled with tandem mass spectrometry, employing the Biocrates® MxP Quant 500 kit. A total of 630 metabolites were assessed using machine learning, as well as multivariate and univariate statistical approaches. Main results and the role of chance Of the 630 metabolites analyzed, 494 were accurately quantified in plasma and 228 in endometrial samples. A distinct metabolomic signature was identified in the endometrium of U-RPL patients, highlighting disruptions in fatty acid metabolism during implantation. Limitations, reasons for caution A limitation of our study is the use of a targeted metabolomics approach, covering only a fraction of the metabolome, although a substantial number of metabolites were quantified. In addition, the absence of genetic analysis of transferred embryos may introduce bias. These findings should be confirmed in larger cohorts. Wider implications of the findings Our study highlights a disruption of fatty acid metabolism in the endometrium during the implantation window in U-RPL, paving the way for the identification of novel biomarkers of endometrial receptivity. Trial registration number Yes
Zitieren
APA
Boguenet, M., Michel, M., Bocca, C., Barca, J. C. D. L., Reynier, P., May-Panloup, P., & Bouet, P. (2026). L26/P-475 Endometrial metabolomic profiling reveals disruption of fatty-acid metabolism in unexplained recurrent pregnancy loss. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.808
Vancouver
Boguenet M, Michel M, Bocca C, Barca JCDL, Reynier P, May-Panloup P, et al. L26/P-475 Endometrial metabolomic profiling reveals disruption of fatty-acid metabolism in unexplained recurrent pregnancy loss. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.808
BibTeX
@article{Boguenet2026,
author = {Boguenet, M. and Michel, M. and Bocca, C. and Barca, J.M. Chao de la and Reynier, P. and May-Panloup, P. and Bouet, P.E.},
title = {L26/P-475 Endometrial metabolomic profiling reveals disruption of fatty-acid metabolism in unexplained recurrent pregnancy loss},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.808}
}
EUVIMED